UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 29, 2005
Impax Laboratories, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 0-27354 65-0403311
- -----------------------------------------------------------------------------------------------------------
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
30831 Huntwood Ave., Hayward, CA 94544
- ----------------------------------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 476-2000
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS
Impax Laboratories, Inc. (the "Company") appointed Arthur A. Koch, Jr.,
age 51, as Senior Vice President, Finance and Chief Financial Officer effective
as of March 29, 2005. Mr. Koch will fill the vacancy created by the retirement
of the Company's former Chief Financial Officer, Cornel C. Spiegler, effective
on that date. Mr. Koch joined the Company in February 2005 as Senior Vice
President, Finance.
For the past seven years of his career, Mr. Koch has worked for
Strategic Diagnostics Inc., a public company that develops, manufactures and
markets immunoassay-based diagnostic test kits. During his tenure with Strategic
Diagnostics, Inc., Mr. Koch held the position of Chief Operating Officer and
Vice President from 1998 to 2004, Interim Chief Executive officer from May 2003
to September 2003, and Chief Financial Officer and Vice President from 1997 to
2002. Mr. Koch has a Bachelor of Business Administration from Temple University
and is a certified public accountant.
A copy of the press release announcing the appointment of Mr. Koch is
furnished as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 - Press Release
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMPAX LABORATORIES, INC.
Date: April 1, 2005 By: /s/ Barry R. Edwards
---------------------------------
Name: Barry R. Edwards
Title: Chief Executive Officer
3